Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Short Interest Down 67.3% in February

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 14,600 shares, a decline of 67.3% from the February 13th total of 44,700 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 59,100 shares, the days-to-cover ratio is currently 0.2 days.

Fresenius SE & Co. KGaA Trading Up 3.7 %

Shares of FSNUY stock traded up $0.39 on Friday, hitting $11.02. 45,104 shares of the company’s stock traded hands, compared to its average volume of 56,628. The stock has a market capitalization of $24.62 billion, a price-to-earnings ratio of 52.48 and a beta of 1.02. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.05 and a current ratio of 1.36. The company’s fifty day simple moving average is $9.79 and its 200 day simple moving average is $9.33. Fresenius SE & Co. KGaA has a one year low of $6.57 and a one year high of $11.16.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last announced its earnings results on Wednesday, February 26th. The company reported $0.18 earnings per share for the quarter. The company had revenue of $6.01 billion for the quarter. Equities analysts forecast that Fresenius SE & Co. KGaA will post 0.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. KGaA in a research note on Monday, February 3rd.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.